Alterations in the NRF2/KEAP1 pathway result in the constitutive activation of NRF2, leading to 23 the aberrant induction of antioxidant and detoxification enzymes, including NQO1. The NQO1 24 bioactivatable agent β-lapachone can target cells with high NQO1 expression but relies in the 25 generation of reactive oxygen species (ROS), which are actively scavenged in cells with 26 NRF2/KEAP1 mutations. However, whether NRF2/KEAP1 mutations influence the response to 27 β-lapachone treatment remains unknown. To address this question, we assessed the 28 cytotoxicity of β-lapachone in a panel of NSCLC cell lines bearing either wild-type or mutant 29 KEAP1. We found that, despite overexpression of NQO1, KEAP1 mutant cells were resistant to 30 β-lapachone due to enhanced detoxification of ROS, which prevented DNA damage and cell 31 death. To evaluate whether specific inhibition of the NRF2-regulated antioxidant enzymes could 32 abrogate resistance to β-lapachone, we systematically inhibited the four major antioxidant 33 cellular systems using genetic and/or pharmacologic approaches. We demonstrated that 34 inhibition of the thioredoxin-dependent system or copper-zinc superoxide dismutase (SOD1) 35 could abrogate NRF2-mediated resistance to β-lapachone, while depletion of catalase or 36 glutathione was ineffective. Interestingly, inhibition of SOD1 selectively sensitized KEAP1 37 mutant cells to β-lapachone exposure. Our results suggest that NRF2/KEAP1 mutational status 38 might serve as a predictive biomarker for response to NQO1-bioactivatable quinones in 39 patients. Further, our results suggest SOD1 inhibition may have potential utility in combination 40 with other ROS inducers in patients with KEAP1/NRF2 mutations.
response to β-lapachone in patients.
Introduction
KEAP1 MUT . To confirm whether β-lapachone promotes cell death via induction of ROS, we 150 supplemented the media with exogenous catalase to increase the antioxidant capacity of the 151 cells ( Figure 2B) . Consistent with prior studies 22,40 , addition of exogenous catalase abrogated β-152 lapachone-induced cell death. Next, we assessed whether KEAP1 MUT cells were protected 153 against β-lapachone-induced DNA damage 32, 39 . We monitored levels of phosphorylated H2A.X 154 (γ-H2AX), a sensitive molecular marker of DNA damage. We observed a time-dependent 155 accumulation of DNA damage in H1299 cells (KEAP1 WT ), while A549 cells (KEAP1 MUT ) did not 156 exhibit increased γ-H2AX following 2-hour treatment with 3 µM β-lapachone ( Figure 2C) . We 165 and HCC15 cells increased γ-H2AX levels following β-lapachone exposure. Lastly, we 166 interrogated ROS and DNA damage levels in NRF2-KO A549s infected with NRF2 WT or an 167 empty control vector after β-lapachone treatment (Figure S2B, S2C) . Consistently, NRF2- To sensitize KEAP1 MUT lung cancer cells to β-lapachone treatment, we sought to identify and 176 inhibit key NRF2-regulated antioxidant pathways. Given the major role of hydrogen peroxide in 177 mediating β-lapachone toxicity, we tested whether inhibition of individual peroxide detoxification 178 systems could overcome β-lapachone resistance (Figure S3A ). First, we tested the relevance 179 of catalase in the sensitivity to β-lapachone by using shRNAs (Figure 3A, 3B) . We observed 180 that depletion of catalase did not affect the β-lapachone sensitivity of NSCLC cells, regardless 181 of KEAP1 mutational status. Of note, we found that H460 cells did not express detectable 182 catalase protein (Figure 3B, S3B) . 
202
These data suggest that although inhibition of the TXN-dependent system increases sensitivity 203 of KEAP1 MUT cells to β-lapachone, the inherent reinforcement of this antioxidant pathway in 204 KEAP1 MUT cells might represent a challenge in vivo. Further, single inhibition of the glutathione 205 or catalase it is not sufficient to increase sensitivity to β-lapachone treatment, suggesting that 206 inhibition of these pathways is compensated by other antioxidant mechanisms.
208

Inhibition of SOD1 potentiates β-lapachone anti-tumor efficacy in KEAP1/NRF2 MUT NSCLC
209
The inherent redundancy in the peroxide detoxification systems represents a major challenge to 210 sensitize KEAP1 MUT cells to ROS generators, as inhibition of one of these pathways may be 211 compensated by other antioxidant enzymes. In contrast, SOD1 has a unique role in catalyzing 212 the dismutation of cytosolic superoxide radicals generated by β-lapachone ( Figure 4A) . Given 213 this unique role of SOD1, we interrogated the effects of SOD1 inhibition on β-lapachone 214 efficacy. We infected KEAP1 MUT cells with virus coding for shRNAs against SOD1 or a non-cell death in KEAP1 MUT cell lines and increased DNA damage (Figure 4B, 4C, S4B ).
217
Importantly, β-lapachone treatment did not change SOD1 activity (Figure S4C ).
219
To validate these findings, we sough to test the effect of pharmacological inhibition of SOD1 on 220 β-lapachone efficacy. However, direct inhibitors of SOD1 that have been shown efficacy in cell- 
226
First, we validated whether we could achieve SOD1 inhibition in cell culture using the copper 227 chelator ATN-224 ( Figure S4D ). We observed that most of SOD1 activity was inhibited after 228 twenty-four-hour treatment using 2.5-5 µM. As expected, copper chelation did not affect SOD2 229 activity. Inhibition of SOD1 resulted in increased sensitivity of KEAP1 MUT cells to β-lapachone-230 mediated cell death and DNA damage (Figure 4D and 4E ). Of note, SOD1 inhibition had little to 231 no effect in KEAP1 WT cells ( Figure 4D) . We also examined the protein levels and activity of 232 SOD1 across our panel of NSCLC cells to evaluate whether KEAP1 MUT cells have higher 233 capacity to detoxify cytosolic superoxide ( Figure S4E ). KEAP1 mutant cells did not exhibit 234 significantly higher levels of SOD1, suggesting that inactivation of KEAP1 does not confer a 235 reinforced capacity to detoxify cytosolic superoxide radicals through SOD1 upregulation.
237
To confirm whether copper chelation sensitizes KEAP1 MUT cells through SOD1 inhibition, A549 238 cells were engineered to express an Escherichia coli manganese-dependent superoxide 239 dismutase enzyme (SodA) to rescue SOD activity. Importantly, SodA expression significantly 240 rescued the effects of copper chelation on β-lapachone treatment (Figure 4F and 4G ).
241
Altogether, these data demonstrate that inhibition of SOD1 selectively increases β-lapachone 242 efficacy in KEAP1 MUT NSCLC cells.
244
Discussion
245
Aberrant NRF2 activation promotes resistance to therapeutics that rely on the production of 246 ROS, including multiple chemotherapeutics and radiation therapy. In this study, we find that 247 NRF2 activation also promotes resistance to the NQO1-activatable prodrug β-lapachone, which 248 relies on the generation of superoxide for its efficacy. While direct NRF2 inhibition could 249 potentially reverse this resistance, NRF2 inhibitors identified to date either lack specificity or potency. Further, the effects of NRF2 whole-body inhibition as anti-tumor strategy remain 251 unclear, as NRF2 activity in necessary for normal functioning of immune cells 45,46 .
253
Consequently, we have evaluated whether inhibition of the cellular antioxidant systems can 254 reverse the resistance of NRF2 active cells to ROS. We find that inhibitors of the TXN-255 dependent peroxide detoxification system and SOD1, but not glutathione or catalase depletion,
256
can reverse the resistance of KEAP1 MUT cells to β-lapachone. Surprisingly, we find that 257 KEAP1 MUT cells were highly resistant to auranofin compared to KEAP1 WT cells, which raises a 258 concern about the toxicity of the required auranofin doses to healthy tissues. The resistance of Figure S4 
